{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:17:04Z","timestamp":1786987024584,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR000433"],"award-info":[{"award-number":["UL1TR000433"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002240"],"award-info":[{"award-number":["UL1TR002240"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA046592"],"award-info":[{"award-number":["P30CA046592"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U24CA204863"],"award-info":[{"award-number":["U24CA204863"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004628","name":"MedImmune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.clgc.2019.03.001","type":"journal-article","created":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T22:25:48Z","timestamp":1552343148000},"page":"e592-e601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Cardiovascular and Metabolic Toxicity of Abiraterone in Castration-resistant Prostate Cancer: Post-marketing Experience"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8694-3186","authenticated-orcid":false,"given":"Phoebe A.","family":"Tsao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason P.","family":"Estes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer J.","family":"Griggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan E.V.","family":"Caram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2019.03.001_bib1","first-page":"1537","article-title":"Treating patients with metastatic castration resistant prostate cancer: a comprehensive review of available therapies","volume":"194","author":"Crawford","year":"2015","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2019.03.001_bib2","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1200\/JCO.2004.03.025","article-title":"How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30","volume":"22","author":"Fromme","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.03.001_bib3","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","article-title":"External validity of randomised controlled trials: \u201cto whom do the results of this trial apply?\u201d","volume":"365","author":"Rothwell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2019.03.001_bib4","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1056\/NEJMp1615879","article-title":"Reevaluating eligibility criteria - balancing patient protection and participation in oncology trials","volume":"376","author":"Beaver","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.03.001_bib5","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.03.001_bib6","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.03.001_bib7","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1016\/j.ejca.2015.06.106","article-title":"The incidence and relative risk of cardiovascular toxicity in patients treated with new hormonal agents for castration-resistant prostate cancer","volume":"51","author":"Iacovelli","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2019.03.001_bib8","first-page":"e38","article-title":"Heart disease and stroke statistics - 2016 update: a report from the American Heart Association","volume":"133","author":"Mozaffarian","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.clgc.2019.03.001_bib9","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0002-8703(86)90155-9","article-title":"Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population","volume":"111","author":"Lerner","year":"1986","journal-title":"Am Heart J"},{"key":"10.1016\/j.clgc.2019.03.001_bib10","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"Keating","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.03.001_bib11","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/cncr.22933","article-title":"Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer","volume":"110","author":"Saigal","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2019.03.001_bib12","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1002\/cncr.24283","article-title":"Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer","volume":"115","author":"Taylor","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2019.03.001_bib13","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1200\/JCO.2014.59.1792","article-title":"Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer","volume":"33","author":"O\u2019Farrell","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.03.001_bib14","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jbi.2015.05.003","article-title":"Supporting information retrieval from electronic health records: a report of University of Michigan\u2019s nine-year experience in developing and using the Electronic Medical Record Search Engine (EMERSE)","volume":"55","author":"Hanauer","year":"2015","journal-title":"J\u00a0Biomed Inform"},{"key":"10.1016\/j.clgc.2019.03.001_bib15","series-title":"Obesity: Preventing and Managing the Global Epidemic: Report of a WHO Consultation","year":"2000"},{"key":"10.1016\/j.clgc.2019.03.001_bib17","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1001\/jama.2015.8035","article-title":"Mortality, hospitalizations, and expenditures for the Medicare population aged 65 years or older, 1999-2013","volume":"314","author":"Krumholz","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.clgc.2019.03.001_bib18","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jama.2011.1474","article-title":"National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008","volume":"306","author":"Chen","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.clgc.2019.03.001_bib19","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.116.022388","article-title":"National trends in atrial fibrillation hospitalization, readmission, and mortality for Medicare beneficiaries, 1999-2013","volume":"135","author":"Freeman","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.clgc.2019.03.001_bib20","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/biomet\/80.1.27","article-title":"Bias reduction of maximum likelihood estimates","volume":"80","author":"Firth","year":"1993","journal-title":"Biometrika"},{"key":"10.1016\/j.clgc.2019.03.001_bib21","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12894-016-0132-z","article-title":"Abiraterone acetate in metastatic castration-resistant prostate cancer - the unanticipated real-world clinical experience","volume":"16","author":"Poon","year":"2016","journal-title":"BMC Urol"},{"key":"10.1016\/j.clgc.2019.03.001_bib22","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/pros.23014","article-title":"Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone","volume":"75","author":"Conteduca","year":"2015","journal-title":"Prostate"},{"key":"10.1016\/j.clgc.2019.03.001_bib23","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/COC.0b013e3182a790ce","article-title":"Safety of abiraterone acetate in castration-resistant prostate cancer patients with concomitant cardiovascular risk factors","volume":"38","author":"Procopio","year":"2015","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clgc.2019.03.001_bib24","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.eururo.2016.02.035","article-title":"Low incidence of corticosteroid-associated adverse events on long-term exposure to low-dose prednisone given with abiraterone acetate to patients with metastatic castration-resistant prostate cancer","volume":"70","author":"Fizazi","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2019.03.001_bib25","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.eururo.2013.09.005","article-title":"Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy","volume":"65","author":"Mulders","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2019.03.001_bib26","first-page":"1277","article-title":"Efficacy and safety of abiraterone acetate in elderly (75 years or older) chemotherapy na\u00efve patients with metastatic castration resistant prostate cancer","volume":"194","author":"Smith","year":"2015","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2019.03.001_bib27","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.eururo.2014.02.056","article-title":"Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)","volume":"66","author":"Rathkopf","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2019.03.001_bib28","doi-asserted-by":"crossref","first-page":"999","DOI":"10.3945\/ajcn.113.071399","article-title":"Obesity paradox in cancer: new insights provided by body composition","volume":"99","author":"Gonzalez","year":"2014","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.clgc.2019.03.001_bib29","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jchf.2013.01.006","article-title":"Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure","volume":"1","author":"Lavie","year":"2013","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.clgc.2019.03.001_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.23876\/j.krcp.2017.36.1.1","article-title":"Kidney disease and obesity paradox","volume":"36","author":"Park","year":"2017","journal-title":"Kidney Res Clin Pract"},{"key":"10.1016\/j.clgc.2019.03.001_bib31","doi-asserted-by":"crossref","first-page":"R72","DOI":"10.1186\/cc12680","article-title":"Clinical characteristics, sepsis interventions and outcomes in the obese patients with septic shock: an international multicenter cohort study","volume":"17","author":"Arabi","year":"2013","journal-title":"Crit Care"},{"key":"10.1016\/j.clgc.2019.03.001_bib32","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s11606-009-1058-x","article-title":"The role of primary care physicians in cancer care","volume":"24","author":"Klabunde","year":"2009","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.clgc.2019.03.001_bib33","doi-asserted-by":"crossref","first-page":"6452","DOI":"10.1200\/JCO.2005.05.026","article-title":"Communication and coordination: the keys to quality","volume":"23","author":"Schrag","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.03.001_bib34","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1056\/NEJMhpr0706165","article-title":"Coordinating care-a perilous journey through the health care system","volume":"358","author":"Bodenheimer","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.03.001_bib35","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.03.001_bib36","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N\u00a0Engl J Med"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767319300540?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767319300540?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:31:39Z","timestamp":1761564699000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767319300540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S1558767319300540"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2019.03.001","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular and Metabolic Toxicity of Abiraterone in Castration-resistant Prostate Cancer: Post-marketing Experience","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2019.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}